{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:47:53Z","timestamp":1782197273697,"version":"3.54.5"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Clone-directed therapy is essential for managing monoclonal gammopathy of renal significance (MGRS), as it reduces the nephrotoxic monoclonal protein burden and preserves renal function. However, due to the rarity and frequent misdiagnosis of MGRS, there is no evidence-based standard first-line treatment for MGRS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This open-label, single-arm, prospective clinical trial assessed the efficacy and safety of the combination of reduced-dose daratumumab (Dara), bortezomib, and dexamethasone (DVd-lite) in ten newly diagnosed MGRS patients. The treatment protocol consisted of six cycles of the DVd-lite regimen, which included Dara (8\u201310 mg\/kg biweekly), bortezomib (1.3 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      weekly) and dexamethasone (5\u201320 mg weekly).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median follow-up duration of this cohort was 13.1 months (range: 4.7-17.6 months). The results showed a hematological overall response rate (ORR) of 80% and a kidney ORR of 90%. Moreover, the complete response rates in hematology and kidney were both 60%. In addition, only one patient experienced a grade 3 treatment-related adverse event.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings demonstrated that the DVd-lite regimen is an effective and well-tolerated first-line treatment option for newly diagnosed MGRS patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.chictr.org.cn\/<\/jats:ext-link>\n                      , identifier ChiCTR2400081273.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1722204","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:12:20Z","timestamp":1782195140000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of reduced-dose daratumumab plus bortezomib and dexamethasone (DVd-lite) in newly diagnosed MGRS patients"],"prefix":"10.3389","volume":"17","author":[{"given":"Huan","family":"Xie","sequence":"first","affiliation":[{"name":"Department of Hematology, Daping Hospital, Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maoyuan","family":"Xiang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Daping Hospital, Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meijuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Daping Hospital, Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanqiao","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Hematology, Daping Hospital, Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Daping Hospital, Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kehong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Daping Hospital, Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongfeng","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Hematology, Daping Hospital, Army Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s2152-2650(24)00332-x","article-title":"Monoclonal gammopathy of renal significance","volume":"384","author":"Leung","year":"2021","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.587345","article-title":"Monoclonal gammopathy of renal significance (MGRS) histopathologic classification, diagnostic workup, and therapeutic options","volume":"77","author":"Amaador","year":"2019","journal-title":"Neth J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2023.0061","article-title":"Multiple myeloma, version 2.2024, NCCN clinical practice guidelines in oncology","volume":"21","author":"Kumar","year":"2023","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26082","article-title":"Waldenstr\u00f6m macroglobulinemia: 2021 update on diagnosis, risk stratification, and management","volume":"96","author":"Gertz","year":"2021","journal-title":"Am J Hematol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41581-018-0077-4","article-title":"The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group","volume":"15","author":"Leung","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-495929","article-title":"How I treat monoclonal gammopathy of renal significance (MGRS)","volume":"122","author":"Fermand","year":"2013","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19956","article-title":"Diagnosis and management of monoclonal gammopathy of renal significance: a British Society for Haematology good practice paper","volume":"206","author":"Pinney","year":"2025","journal-title":"Br J Haematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2021.1971192","article-title":"Consolidation with a short course of daratumumab in patients with AL amyloidosis or light chain deposition disease","volume":"28","author":"Kastritis","year":"2021","journal-title":"Amyloid"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001553","article-title":"Daratumumab in light chain deposition disease: rapid and profound hematologic response preserves kidney function","volume":"4","author":"Palladini","year":"2020","journal-title":"Blood Adv"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2020101541","article-title":"Safety and efficacy of daratumumab in patients with proliferative GN with monoclonal immunoglobulin deposits","volume":"32","author":"Zand","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17052","article-title":"Daratumumab\u2010based therapy for patients with monoclonal gammopathy of renal significance","volume":"193","author":"Kastritis","year":"2020","journal-title":"Br J Haematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2022.103623","article-title":"Management of infectious risk of daratumumab therapy in multiple myeloma: a consensus-based position paper from an ad hoc Italian expert panel","volume":"172","author":"Girmenia","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1182\/blood-2019-127247","article-title":"Hypogammaglobulinemia and its implications in patients treated with daratumumab: a single institution experience","volume":"134","author":"Paul","year":"2019","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41408-024-01082-y","article-title":"Anti-CD5 CAR-T cells with a tEGFR safety switch exhibit potent toxicity control","volume":"14","author":"Lin","year":"2024","journal-title":"Blood Cancer J"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2026.102584","article-title":"Efficacy and safety of autologous CD5-KO anti-CD5 CAR-T cells in relapsed\/refractory CD5(+) hematological Malignancies","volume":"7","author":"Cheng","year":"2026","journal-title":"Cell Rep Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/nejmoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26155","article-title":"The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance","volume":"96","author":"Castillo","year":"2021","journal-title":"Am J Hematol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26566","article-title":"Monoclonal gammopathy of renal significance (MGRS): real\u2010world data on outcomes and prognostic factors","volume":"97","author":"Gozzetti","year":"2022","journal-title":"Am J Hematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2015.201","article-title":"Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease","volume":"88","author":"Cohen","year":"2015","journal-title":"Kidney Int"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2147\/ijgm.s386733","article-title":"A review on the diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits","volume":"15","author":"Lin","year":"2022","journal-title":"Int J Gen Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1722204\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:12:20Z","timestamp":1782195140000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1722204\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":22,"alternative-id":["10.3389\/fimmu.2026.1722204"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1722204","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"article-number":"1722204"}}